دورية أكاديمية
Immune Checkpoint Inhibitors: The Emerging Cornerstone in Cholangiocarcinoma Therapy?
| العنوان: | Immune Checkpoint Inhibitors: The Emerging Cornerstone in Cholangiocarcinoma Therapy? |
|---|---|
| المؤلفون: | Gutiérrez Larrañaga, María, González López, Elena, Roa Bautista, Adriel, Rodrigues, Pedro M., Díaz González, Álvaro, Bañales Asurmendi, Jesús María, López Hoyos, Marcos, Santos Laso, Álvaro, Crespo, Javier |
| بيانات النشر: | Karger |
| سنة النشر: | 2021 |
| المجموعة: | ADDI: Repositorio Institucional de la Universidad del País Vasco / Euskal Herriko Unibertsitatea (UPV/EHU - Basque Country University) |
| مصطلحات موضوعية: | cholangiocarcinoma, therapy, prognosis, clinical trials, immune checkpoint inhibitors |
| الوصف: | [EN]Background: Cholangiocarcinoma (CCA) encompasses a heterogeneous group of malignant tumors with dismal prognosis and increasing incidence worldwide. Both late diagnosis due to the lack of early symptoms and the refractory nature of these tumors seriously compromise patients' welfare and outcomes. Summary: During the last decade, immunotherapy and, more specifically, modulation of immune checkpoints-mediated signaling pathways have been under the spotlight in the field of oncology, emerging as a potential therapeutic approach for the treatment of several cancers, including CCA. Generally, high expression levels of immune checkpoints in patients with CCA have been associated with worse clinical outcomes, particularly with shorter overall survival and relapse-free survival. Thus, immune checkpoint inhibitors (ICIs), which mainly constitute different monoclonal antibodies, have been developed in order to hamper the immune checkpoint-mediated pathways. Interestingly, chemotherapy may increase the expression of immune checkpoints, while other therapeutic approaches such as ablative and targeted therapies may enhance their antitumor activity. In this sense, several clinical trials evaluated the safety and efficacy of ICIs for CCA, both as a monotherapy and in combination with other ICIs or loco-regional and systemic therapies. Additionally, many other clinical trials are currently ongoing and results are eagerly awaited. Here, we summarize the key aspects of immune checkpoint molecules as prognostic factors and therapeutic targets in CCA, highlighting the most recent advances in the field and future research directions. Key Messages: (1) Effective therapeutic approaches for CCA are urgently needed. (2) Expression levels of immune checkpoints in patients with CCA have been proposed to be related with clinical outcomes. (3) Combination of different ICIs may outperform the efficacy of ICI monotherapy for CCA treatment. (4) Recent studies point toward the combination of ICIs and other common therapies, especially ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 2235-1795 1664-5553 |
| العلاقة: | https://www.karger.com/Article/FullText/518104Test; Liver cancer 10(6) : 545–560 (2021); http://hdl.handle.net/10810/54854Test |
| DOI: | 10.1159/000518104 |
| الإتاحة: | https://doi.org/10.1159/000518104Test http://hdl.handle.net/10810/54854Test |
| حقوق: | info:eu-repo/semantics/openAccess ; http://creativecommons.org/licenses/by-nc/3.0/esTest/ ; © 2021 The Author(s). This is an Open Access article licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicenseTest), applicable tothe online version of the article only. Usage and distribution for commercial purposes requires written permission. ; Atribución-NoComercial 3.0 España |
| رقم الانضمام: | edsbas.3C19F85 |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 22351795 16645553 |
|---|---|
| DOI: | 10.1159/000518104 |